Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 11/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21369617 | 0.99 | MEN1 (0.47) | MEN1CYP2D6KMT2AOGAKDM4E | |
| SCHEMBL21369470 | 0.87 | ALDH1A1 (0.51) | CYP2D6KDM4EALDH1A1TRPV4SMN1; SMN2 | |
| SCHEMBL25626468 | 0.85 | ALDH1A1 (0.49) | MEN1CYP2D6KMT2AKDM4EALDH1A1 | |
| SCHEMBL21369471 | 0.82 | MEN1 (0.47) | MEN1CYP2D6KMT2AOGAKDM4E | |
| SCHEMBL21369577 | 0.81 | CRHR1 (0.43) | KMT2AKDM4EALDH1A1TRPV4SMN1; SMN2 | |
| SCHEMBL24862759 | 0.80 | OGA (0.57) | MEN1CYP2D6KMT2AOGAKDM4E | |
| SCHEMBL21369466 | 0.80 | CRHR1 (0.42) | KMT2AOGAKDM4EALDH1A1TRPV4 | |
| SCHEMBL21370310 | 0.79 | OGA (0.58) | OGAKDM4EALDH1A1POLB | |
| SCHEMBL28568842 | 0.76 | OGA (0.53) | CYP2D6OGA | |
| SCHEMBL28564168 | 0.76 | OGA (0.70) | CYP2D6OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150483-A1 | REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4186899-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3829716-B1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3630755-B1 | 5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS | LILLY CO ELI (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3573983-B1 | N-[4-FLUORO-5-[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR | LILLY CO ELI (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2018140299-A1 | N-[4-FLUORO-5-[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | WO | disclosed |